Soluble urokinase plasminogen activator receptor (suPAR) in the emergency department: An update.
Open Access
- journal article
- Vol. 13 (4) , 650-665
Abstract
The biomarker soluble urokinase plasminogen activator receptor (suPAR) is an indicator of inflammation which is increased in a variety of chronic and acute disease states. Its most promising application in the emergency setting is to aid in the prognostic stratification of patients by identifying those at high risk of deterioration. This is a narrative review of studies evaluating the use of suPAR. We conducted a Medline search for studies on the use of suPAR in patients acutely admitted to the emergency department. 25 original studies were included in the review. suPAR as a marker of inflammation has been used alone or combined to other inflammatory biomarkers in the assessment of patients suffering from various acute and chronic diseases in an emergency setting. As it is non-specific, it may increase in infectious disease, malignancy or acute coronary syndromes among other conditions, but quantitative suPAR levels correlate with disease severity. It may be useful for the identification of high risk patients regardless of underlying pathology. As the ideal biomarker in the emergency setting has not been identified yet, suPAR may be a promising addition to the established biomarkers for the initial assessment of patients in this setting. Additional research is necessary to evaluate the usefulness of suPAR guided management algorithms.Keywords
This publication has 32 references indexed in Scilit:
- Clinical Evaluation of Multiple Inflammation Biomarkers for Diagnosis and Prognosis for Patients with Systemic Inflammatory Response SyndromeJournal of Clinical Microbiology, 2014
- Soluble urokinase plasminogen activator receptor predicts mortality in patients with systemic inflammatory response syndromeJournal of Internal Medicine, 2014
- Biomarkers and Molecular Analysis to Improve Bloodstream Infection Diagnostics in an Emergency Care UnitPLOS ONE, 2014
- Soluble Urokinase Plasminogen Activator Receptor for Risk Prediction in Patients Admitted with Acute Chest PainClinical Chemistry, 2013
- Diagnostic accuracy of soluble urokinase plasminogen activator receptor (suPAR) for prediction of bacteremia in patients with systemic inflammatory response syndromeClinical Biochemistry, 2013
- Soluble urokinase‐type plasminogen activator receptor in patients with suspected infection in the emergency room: a prospective cohort studyJournal of Internal Medicine, 2012
- Plasma suPAR levels are associated with mortality, admission time, and Charlson Comorbidity Index in the acutely admitted medical patient: a prospective observational studyCritical Care, 2012
- suPAR as a prognostic biomarker in sepsisBMC Medicine, 2012
- Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general populationJournal of Internal Medicine, 2010
- Use of plasma C-reactive protein, procalcitonin, neutrophils, macrophage migration inhibitory factor, soluble urokinase-type plasminogen activator receptor, and soluble triggering receptor expressed on myeloid cells-1 in combination to diagnose infections: a prospective studyCritical Care, 2007